CBRE is pleased to offer to market the freehold interest in the medical asset leased to HPS Pharmacies (backed by ASX: EBOS Group) and Linear Clinical Research, Joondalup WA for sale via our Investment Portfolio 188.

This opportunity has the following key investment highlights:

+ Five (5) year net lease to HPS Pharmacies to November 2029 with options to 2031.
+ HPS Pharmacies: founded in 1975, is one of Australia’s leading providers of pharmacy services to health facilities, including private hospitals, public hospitals, cancer centres and veterinary clinics. (1)
+ HPS Pharmacies is backed by EBOS Group Limited (ASX: EBO). EBOS Group is the largest Australasian wholesaler and distributor of healthcare, medical and pharmaceutical products. (2)
+ Purpose built hospital grade pharmacy compounding laboratory.
+ Direct continuity of care to Joondalup Health Campus via dedicated pneumatic tube network, Fibre Optic pairs and CAT5 point-to-point campus integration.
+ Landlord favourable rent increases.
+ Investor preferred net lease terms with HPS Pharmacies and Linear Clinical Research responsible for all outgoings including land tax, rates, insurance premiums & management fees.
+ Modern & well presented 669sqm* building offering purpose built pharmacy compounding centre and more.
+ Highly strategic 1,084sqm* landholding with 26 on-title car spaces.
+ Dominant medical precinct position with Ramsay Healthcare’s Joondalup Health Campus 10 metres from the property boundary.
+ City of Joondalup: home to some 176,595 residents and some of Perth’s largest community infrastructure assets. Joondalup is the central hub of Perth’s northern corridor and is home to the city’s Joondalup Health Campus, Lakeside Joondalup Shopping City and many more attractions making it one of Perth’s most livable locations. (3)
+Net Income: $252,900 pa* + GST

To be sold via Portfolio Expressions of Interest
1:00pm (AWST) Thursday 29 October 2026

Approx*
(1) HPS Pharmacies
(2) EBOS Group Limited
(3) ABS